secwatch.observer — SEC 8-K summary
======================================

Issuer:     CalciMedica, Inc. (CALC)
CIK:        0001534133
Form:       8-K
Filed at:   2022-11-10T23:59:59+00:00
Accession:  0001193125-22-282783
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Graybug Q3 net loss $9.8M; terminates GB-102/401 programs, cuts 20 of 28 staff
------------------------------------------------------------------------------

- Net loss $9.8M in Q3 2022 vs $8.0M in Q3 2021; nine-month loss $28.2M vs $27.1M.
- In August 2022, terminated 20 of 28 employees and wound down GB-102 (Phase 2b) and GB-401 programs; restructuring charge $2.4M.
- R&D expense fell to $3.2M from $4.0M due to program halt; G&A rose to $4.3M from $4.0M on stock-based compensation.
- Cash, equivalents, and short-term investments $43.6M; cash runway beyond 2023 subject to ongoing strategic review.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534133/000119312522282783/0001193125-22-282783-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534133/000119312522282783/d407208d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-282783

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer